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Vulnerable plaques
The majority of coronary thrombi (75%) is caused by plaque
rupture.1,2 Prototype of the rupture-prone plaque contains a large,
soft, lipid-rich necrotic core with a thin and inflamed fibrous cap,
so-called thin-cap fibroatheroma (TCFA) (Figure 1).3,4 Other
common features include expansive remodelling, large plaque size,
plaque haemorrhage, neovascularization, adventitial inflammation,
and ‘spotty’ calcifications.4 Thin-cap fibroatheroma caps are usually
,65 mm thick.4 Figure 2 summarizes factors contributing to the for-
mation of vulnerable plaques. No distinct morphological features
have been identified for the erosion-prone plaques, but they are
usually rarely associated with expansive remodelling, scarcely calci-
fied, and contain only limited inflammation.2,5
Inflammatory cells, cytokines,
chemokines, and growth factors
Vulnerable plaques containmonocytes, macrophages, and T-cells. Of
the T-cells, CD4+ T-helper (Th) cells are the most prominent.6
T-cells can differentiate into a Th1 phenotype, which secretes and
responds to IFN-gor a Th2 phenotype, which secretes and responds
to IL-4, IL-10, and IL-13 (Figure 3). T-cells promote the vulnerability of
plaques through their effects on macrophages. Similarly, there are
two main plaque macrophage phenotypes: pro-inflammatory M1
macrophages (IFN-g-induced) and anti-inflammatory or regulatory
M2 macrophages (IL-4/IL-13-induced).7
Cytokines and chemokines important for regulating inflammatory
and immune responses are listed in Supplementary material online,
Table S1.7 –11 The concept that Th1-related pro-inflammatory cyto-
kines drive progression whereas Th2- and regulatory T-cell-related
cytokines exert anti-atherogenic effects provides a useful theoretical
framework (Figure 3). For an unstable phenotype, IFN-g, IL-12, and
IL-18 seem to be important factors. CCR5 drives Th1-type
pro-inflammatory responses and contributes to plaque formation.12
Important players for plaque destabilization are macrophage migra-
tion inhibitory factor (MIF)13 and monocyte chemotactic
protein-1.14 Of the plaque-stabilizing factors, IL-10 and TGF-b are
of the greatest significance.11,15
Extracellular proteases and platelets
Extracellular proteases correlate with changes associated with
plaque vulnerability,16 such as macrophage ingress and apoptosis,
and loss of collagen and elastin.17,18 Apoptosis of SMCs contributes
to weakening of plaques. Knockout models supported a role for
matrix metalloproteinases (MMPs)19 and cathepsins20 in plaque
rupture, although the effects of MMP inhibitors on plaque stability
have been mixed. Recent studies with more selective drugs21
provide new hope that inhibiting proteases or preventing their secre-
tion19 may lead to plaque stabilization.
Platelets contribute to atherogenesis through secretory functions
and as modulators of inflammatory responses. Antiplatelet drugs
might, therefore, serve as plaque-stabilizing compounds. However,
experimental data on antiplatelet drugs are contradictory.22– 25 Al-
though antiplatelet drugs have proven benefits in the secondary pre-
vention of CVD, their direct role in plaque stabilization remains
unclear.
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Endothelial dysfunction, wall stress,
and shear stress
Impairment in endothelium-dependent vasodilatation is the clinical
hallmark of endothelial dysfunction.26 In atherosclerosis, there is
coexistence of segments with normal vasodilatory and abnormal
vasoconstrictive responses to acetylcholine. In virtual histology
(VH)-intravascular ultrasound (IVUS), segments with endothelial
dysfunction have larger plaques and necrotic core areas.27 Under
sympathetic activity, dysfunctional endothelium will respond with
paradoxical vasoconstriction. The release from platelets of peptides,
in particular serotonin and thrombin, leads to further vasoconstric-
tion and perpetuation of the situation.28 –31
Shear stressplays a key roleduring initiationof atherosclerosis.32,33
Recent studies indicate that it also predicts location of advanced
lesions.34 Repeated measurements indicate that low shear stress is
predictive of not only plaque location, but also of plaque
growth.35,36 Role of wall stress in plaque rupture has been increasing-
ly recognized, since it seems to predict plaque rupture better than
shear stress.37 The levels of these forces inducing rupture are in
the order of 150 kPa or 1100 mmHg, which have been shown
to occur at the shoulder regions.37 In the PREDICTION trial, large
plaque burden and low local endothelial shear stress provided inde-
pendent and additive prediction to identify plaques that develop pro-
gressive enlargement and lumen narrowing.38
Angiogenesis
Microvessels increase with plaque progression, are abundant in vul-
nerable plaques,39 and can contribute to plaque inflammation.40
Fragile microvessels allow extravasation of lipoproteins and red
blood cells,41 which contribute to plaque lipids. Whether haemor-
rhage from neovessels triggers plaque rupture (or vice versa)
remains to be demonstrated. Mechanisms regulating plaque angio-
genesis involve hypoxia-inducible factor and growth factors, such
as VEGFs, PlGF, PDGFs, and FGFs.42 However, the net effect of all
these regulators remains unclear.WhileVEGF is expressed in athero-
sclerotic lesions,43 patients receiving anti-VEGFantibodies for cancer
show increased CVD complications. This finding is compatible with
vasculoprotective effect of VEGF, and transient treatment of mice
with VEGF has not increasedatherosclerosis.44 Whether therapeutic
manipulation of angiogenesis can stabilize plaques remains to be
investigated.45
Figure 2 Factors contributing to the formation of vulnerable plaques. MCP-1, monocyte chemotactic protein-1; MIF, migration inhibitory factor;
TNFa, tumour necrosis factor-a; ILs, interleukins; MMPs, matrix metalloproteinases; TIMPs, tissue inhibitorsof metalloproteinases; PDGFs, platelet-
derived growth factors; VEGFs, vascular endothelial growth factors; FGFs, fibroblast growth factors; Mf, macrophages.
Figure 1 Cross-sectioned coronary artery showing a ruptured
thin-cap fibroatheroma. The fibrous cap is very thin near the
rupture site (between arrows) and a non-obstructive mural throm-
bus (asterisks) is bordering the gap in the disrupted cap. A haemor-
rhage has penetrated from the lumen through the gap into the
lipid-rich necrotic core in which the characteristic cholesterol
clefts are clearly seen. The lumen contains contrast medium
injected postmortem. Overview in inset. Trichrome, staining colla-
gen blue, and thrombus and haemorrhage red.
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Progenitor cells
Clinical studies show correlations of endothelial progenitor cells
(EPCs) with atherogenesis,46 suggesting that EPCs may provide pro-
tection against atherosclerosis. Recent data, however, question these
findings: putative EPCs measured in the clinics have generated mostly
inflammatory cells rather than endothelial cells.47 Also, mouse
studies tracking endothelial origin in atherogenesis have found rare,
if any, contributions from the blood.48
Smoking
Smoking is a major CVD risk factor causing endothelial damages,
disturbances in coagulation, and inflammation.49 Stopping smoking
is beneficial for plaque stabilization.
Biomarkers, genetic testing, and
imaging in the detection of unstable
plaques
Biomarkers and genetic testing
Single nucleotide polymorphism and GWAS studies have identified
approximately 160 genetic loci that are associated with CVD, MI,
and restenosis.50,51 However, there are no data to pinpoint specific
genetic signatures to the vulnerable plaque. Although a genetic test
to identify patients who carry vulnerable plaques is the ultimate
goal, this seems currently unlikely. It seems clear that part of the
gene–environment interactions are regulated by epigenetics.52 As
chromatin alterations are reversible, epigenetic modifications are
amendable to pharmacological interventions, which may provide
new treatments for CVD.
Detection of unstable plaques
Plaque burden correlates well with calcification, but is not an indica-
tor of stability. Computerised tomography shows that lesion area in
ruptured plaques is larger than in stable lesions.53 Using IVUS, it was
found that patients with acute MI had larger plaque area compared
with patients with unstable or stable angina. VH-IVUS allows classifi-
cation of lesions as fibrous, fibrocalcific, fibroatheroma, and
TCFAs.54 The definition of IVUS-derived TCFA is a lesion with
plaque burden ≥40% and confluent necrotic core ≥10% in direct
contact with lumen. VH-IVUS identified the following characteristics
as predictors of clinical events5: TCFA, plaque burden ≥70%, and
minimum lumen area ≤4 mm2. However, even combining these
characteristics resulted in only 18% event rate during 3 years,
which illustrates current limitations of imaging techniques.
Optical coherence tomography (OCT) gives a spatial resolution of
≤20 mm allowing more accurate assessment of cap thickness
(Figure 4).55 Optical coherence tomography has potential to assess
plaquemacrophagecontent. Innon-flow-limitingcoronary lesions,high-
risk plaque characteristics (such as thin fibrous cap, large lipid pools, and
microchannels) were associated with plaque progression.56 NIR spec-
troscopy is another technique designed to identify lipid-containing
plaques.57 Emerging imaging techniques utilize MRI markers homing
to rupture-prone plaques and markers of macrophage metabolic activ-
ity.58 Developing such techniques remains a challenge for the future.59
Current treatments and future
perspectives of plaque stabilization
Statin therapy
Patients receiving pravastatin 3 months before carotid endarterec-
tomy showed significantly less inflammation and a higher collagen
content in carotid plaques, suggesting plaque stabilization.60 The
ATROCAP study randomized two-step bilateral carotid endather-
ectomy patients to atorvastatin or placebo for 4–6 months
after the first procedure. Plaques from treated patients showed a
trend towards fewer inflammatory cells, whereas no change was
observed in controls.61 Results are consistent with pleiotropic,
anti-inflammatory effects of statins, which may contribute to the sta-
bilization of plaques.62 Recent experimental finding of plaque stabil-
ization with ezetimide, which lacks pleiotropic effects, lends support
to the lipid-lowering therapy per se.63 However, it is not yet possible
to discern the contribution of each mechanism to clinical results.
The German Atorvastatin Study demonstrated that hyperecho-
genicity of plaques significantly increased after 12 months compared
with non-statin-based lipid lowering.64 In the ASTEROID65 and
SATURN studies,66 aggressive lipid lowering regressed atheroma
volume in IVUS. Data from several prospective IVUS trials confirmed
Figure 3 Diverse leucocyte populations in atherosclerotic
plaques. Depending on the context of antigen presentation includ-
ing the cytokine environment, naı¨ve T-cells and macrophages may
adopt several phenotypes that are more or less inflammatory. Po-
larization of the environment is promoted by the positive and nega-
tive interactions indicated.Th1, Th2, Treg: T-cell subtypes; M1, M2a,
M2c: macrophage subtypes.
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significant atheroma regression after LDL reduction67 and the
PROVE-IT trial showed lower CVD endpoints after 24 months
under intense lipid lowering in ACS patients.68 In addition, the
JUPITER study in healthy subjects with LDL ,3.4 mmol/L and
hs-C-reactive protein above 2 mg/L showed that 20 mg of rosuvasta-
tin significantly reduced major CVD events in this low-risk group.69
Antiplatelet and antihypertensive
therapies
Aspirin is effective for CVD secondary prevention, and a major re-
duction in CVD events was found in the CURE trial, where clopido-
grel was added to aspirin in ACS patients.70 However, these agents
mostly reduce complications of plaque rupture and may not be
plaque-stabilizing agents per se. Whether new platelet inhibitors
ticagrelor and prasugrel and platelet thrombin receptor inhibitor
vorapaxar have plaque-stabilizing properties remains unknown,
although recent meta-analyses have suggested the same benefits in
patients with recent ACS.71
Four recent IVUS trials have shownthatb-blockers slowtheprogres-
sion of CVD.72 Endothelial function can be improved by renin–angio-
tensin inhibitors, and HOPE73 and ONTARGET74 trials have shown a
larger reduction in CVD events that could be predicted from the reduc-
tion in blood pressure, supporting plaque-stabilizing effects.
Other anti-atherosclerotic therapies
HDL-raising therapies
ApoA1-Milano and other HDL-like apoA1 complexes have been
shown to regress atherosclerosis possibly via several HDL-related
Figure 4 Serial and corresponding virtual histology and optical coherence tomography. (A) The baseline optical coherence tomography frame
(top), the corresponding virtual histology frame (mid), and the quantification of the virtual histology tissue types (bottom). The optical coherence
tomography frame shows from 8 to 12 o’clock a fibroatheroma which is composed of a fibrous cap (white arrow) and a necrotic core (asterisk). The
corresponding virtual histology frames showalso a fibroatheroma (necrotic core-rich plaque in red colour). In (B), the patient was reimaged at 1 year
and some plaque changes have been observed. In the optical coherence tomography frame, the fibrous cap became thinner (please note that at
baseline, the signal rich area overlying the necrotic core was wider).
S. Yla¨-Herttuala et al.3254
protective mechanisms like reverse cholesterol transport, anti-
oxidative activity, endothelial vasoprotection, and reduction of plate-
let activation.75 HDL also inhibits coagulation cascade. Cholesterol
ester transfer protein (CETP) is a plasma protein that catalyses
exchange of cholesteryl esters and triglycerides between lipopro-
teins.Reduction inCETPactivity is associatedwithcholesterol reduc-
tion in VLDL and LDL and enrichment of HDL. However, the
ILLUMINATE trial with a CETP inhibitor torcetrapib failed due to
toxicity.76 New trials with novel CETP inhibitors such as anacetrapib
(Supplementary material online, Table S2) are underway, but
dal-OUTCOMES trial assessing dalcetrapib has been stopped due
to the lack of efficacy.77 Thus, these recent trials and a large Mendel-
ian randomization study78 question the usefulness of HDL-raising
therapies, if no simultaneous beneficial changes can be achieved in
VLDL or LDL levels.
Niacin/nicotinic acid
With interest in HDL-raising therapies, niacin has been recently
re-investigated. Two trials in statin-treated patients with low HDL
have shown that modified-release nicotinic acid significantly
reduced carotid atherosclerosis,79 and that the use of slow-release
niacin significantly reduced carotid intima-media thickness in com-
parison with statin.80 However, AIM-HIGH and HPS-2-THRIVE
trials failed to show any added benefits (Supplementary material
online, Table S2), which raises doubts about the usefulness of this
approach.
Phospholipase inhibitors
Another approach to reduce plaque inflammation is to inhibit
lipoprotein-associated phospholipase A2, which has prevented in-
crease in necrotic core when compared with placebo.81 Two
major trials testing this approach are now ongoing (STABILITY and
SOLID-TIMI 52 trials).
New approaches
Antagonists against pro-atherogenic chemokine receptor CCR5 and
its ligand CCL5 have been developed.82 Migration inhibitory factor is
involved in atheroprogression and its inhibition with biologicals or
small molecules may be useful for plaque stabilization.13
PCSK9 is involved in hypercholesterolaemia by favouring degrad-
ation of LDL receptor.83 Some natural PCSK9 mutations increase its
function and cause hypercholesterolaemia, whereas loss-of-function
mutations cause hypocholesterolaemia. Therefore, PCSK9 is an
attractive target for lowering plasma LDL with potential plaque-
stabilizing features. The ODYSSEY OUTCOMES trial is now testing
the efficacy of PCSK9 inhibitor in CVD (Supplementary material
online, Table S2).
siRNAs against apoB100 have been used to reduce LDL levels.84
Whether this technology will be useful in the prevention of plaque
ruptures remains unknown. Innate and adaptive immunity regulates
pro-atherogenic inflammation. Immunization of hyperlipidaemic
animals with LDL preparations or apoB100 fragments reduces ath-
erosclerosis, suggesting that vaccination may become a potential
strategy for the prevention of CVD.85,86
Supplementary material
Supplementary material is available at European Heart Journal online.
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Accidental stent fracture due to chest trauma after percutaneous
Melody valve implantation
Sven Hormann, Walter Knirsch*, and Oliver Kretschmar
Division of Cardiology, University Children’s Hospital Zurich, Steinwiesstrasse 75, Zurich 8032, Switzerland
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A 12-year-old boy was treated with percutaneous
Melody valve implantation (Medtronic, Inc., USA)
due to a severe right ventricular (RV) to pulminary
artery (PA) homograft stenosis. Two years later,
while playing at a swimming pool, the boy received
a powerful and unexpected hit to his back by a
rubber tyre. He immediately complained about
severe back and chest pain, general weakness,
nausea, and one episode of syncope during exer-
tion. Doppler echocardiography revealed a new
severe pulmonary (Melody) valve stenosis with a
narrowed lumen and a free floating structure
inside (Panel A). Cardiac catheterization revealed
severe RV-PA obstruction (peak-to-peak-gradi-
ent 40 mmHg). This was caused by fractures
of anterior and proximal stent struts of the
Melody valve just behind sternal boarder (‘‘coup
contre-coup’’ mechanism) leading to dynamic nar-
rowing of the stent lumen by protruding like an
additional valve into the vessel lumen during
systole (Panel B, asterisks; Supplementary material
online, Video loop S1). Melody valve integrity itself
was not affected. Therefore, implantation of a
second Melody valve inside the old valve
(‘‘valve-in-valve’’) was carried out. After interven-
tion, Melody valve position and function were excellent (Panel C; Supplementary material online, Video loop S2). On echo, at discharge 3
days later, Melody valve showed a laminar flow pattern (Panel D).
Coup contre-coup mechanism due to accidental chest trauma may cause strut fractures of the valved stent due its anatomic nearness to
sternal border. In this situation, a percutaneous valve-in-valve procedure has to be considered. This can be performed safely and avoids
cardiopulmonary bypass surgery.
Supplementary material is available at European Heart Journal online.
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